SCHEMBL3596396

SCHEMBL3596396

CCOC(=O)Nc1c(C)cc(C=O)cc1C

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 10/20 0.60
SMN1; SMN2 Q16637 2/20 0.49
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
KDM4E B2RXH2 4/20 0.44
GLA P06280 1/20 0.44
POLB P06746 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3607994 0.89 NLRP3 (0.52) NLRP3SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL3600751 0.84 NLRP3 (0.48) NLRP3SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL26588963 0.82 NLRP3 (0.78) NLRP3SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL6005086 0.80 SMN1; SMN2 (0.69) NLRP3SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL1000325 0.79 NLRP3 (0.59) NLRP3SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL11715963 0.79 NLRP3 (0.59) NLRP3SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL4088389 0.79 TSHR (0.54) NLRP3KDM4EGLAPOLBALDH1A1
SCHEMBL348699 0.76 SMN1; SMN2 (0.50) NLRP3SMN1; SMN2KDM4EPOLBALDH1A1
SCHEMBL20702812 0.75 NLRP3 (1.00) NLRP3SMN1; SMN2ALDH1A1HPGD
SCHEMBL9359788 0.75 NLRP3 (0.78) NLRP3SMN1; SMN2CYP1A2CYP2C9KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100063044-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2010-03-11 US disclosed
US-7601870-B2 Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy H. LUNDBECK A/S (DK) 2009-10-13 US disclosed
EP-1791809-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2007-06-06 EP disclosed
US-20060155121-A1 Substituted aniline derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2006029623-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063044-A1 SUBSTITUTED ANILINE DERIVATIVES NDUFS3, NAT1, PRMT3 NLRP3 3233/4885SMN1; SMN2 4052/4885CYP1A2 19/4885
US-20060155121-A1 Substituted aniline derivatives UGT2B7, NAT1, CYP1A2 NLRP3 4464/4885SMN1; SMN2 1908/4885CYP1A2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.